Learning Disability Treatment Market

Market Insight

The learning disability treatment market is set to reach US$ 30,493.1 million by 2027 from US$ 17,418.0 million in 2018, highlighting steady growth at a compounded annual growth rate (CAGR) of 6.5% during the forecast period from 2019 to 2027.

Children with learning disabilities have tremendous mental ability, but due to irregular impulses generated by the central nervous system, they suffer from altered behavior and lower cognitive skills. If diagnosed at an early stage, the proper medical intervention will improve the quality of life for the patient suffering from a learning disability.

Market Synopsis

Excellent therapeutic efficacy and rising popularity among psychiatrists drive the demand for stimulant and non-stimulant medication.

Stimulant and non-stimulant medications are leading the therapy segment for the learning disability treatment market. Psychoactive drugs such as Ritalin, Focalin, Dexedrine, and Vynase are prescribed for improving central nervous system activity by blocking the uptake of catecholamines such as dopamine and norepinephrine.

Non-stimulants are also prescribed to treat depression and anxiety in a few patients suffering from ADHD. In addition, assistive technology is gaining huge traction owing to its ability to provide cognitive behavioral therapy and occupational therapy in the form of learning applications and software to aid teachers in helping kids with dyslexia and dyspraxia.

A comprehensive evaluation test and critical assessment of underlying language skills result in an early diagnosis of dyslexia.

Dyslexia is reigning in the indications segment for the learning disability treatment market. According to research conducted by the International Dyslexia Association (IDA), the prevalence rate of dyslexia in children qualifying for special education is 6–7%. The core problem associated with dyslexia is difficulty in word recognition, reading and writing fluency, etc.

A comprehensive evaluation test and critical assessment of underlying language skills result in an early diagnosis of dyslexia and interventional therapy. Attention deficit hyperactivity disorder (ADHD) has a worldwide prevalence rate of 2.2%, with a higher occurrence in males in comparison to females.

Effective clinical guidelines have been designed by psychiatrists worldwide with an effective combination of pharmacological drugs and occupational and cognitive-behavioral therapy to treat ADHD effectively.

In North America, the market is being driven by the rising prevalence of ADHD and proactive government initiatives to promote awareness and treatment for mentally disabled children.

North America is presently dominating the regional segment of the learning disability treatment market, holding a market share of 32.5%. The major factor responsible for its outstanding market growth is the rising prevalence of attention deficit hyperactivity disorder (ADHD); as per the statistics provided by the American Psychiatric Association (APA), in 2016, approximately 6.1 million children were diagnosed with ADHD in North America.

Proactive government initiatives to promote awareness and treatment for mentally disabled children further bolster market growth. Europe represents a 29% market share on account of the rising prevalence of dyslexia across all age groups. According to the European Dyslexia Association (EDA) research, dyslexia affects between 9% and 12% of the population.

The Asia Pacific holds an 18.5% market share owing to the rampant growth in schools and institutes to treat children with learning disabilities and the significant rise in assistive technology focusing on the development of learning software and applications in compliance with occupational therapy.

Periods of History and Forecast

This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. In addition, the compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market segmentation for the report’s scope is done by therapy, indication, and geography.

According to Indication (2017-2027; US$ Mn)

• Attention Deficit Hyperactivity Disorder (ADHD)
• Dyslexia
• Dyspraxia
• Others

Geography Segment (US$ Mn; 2017-2027)

• North America (U.S., Canada)
• Europe (U.K., Germany, rest of Europe)
• Asia Pacific (China, Japan, and the Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• the Middle East and Africa (GCC and the rest of the MEA)

IT-Healthcare, in collaboration with pharmaceutical companies actively participating in the learning disability treatment market, includes CogniFit, Eli Lilly & Company, Forest Laboratories, Inc., IMSE, Novartis AG, Pfizer, Inc., Shire Plc., Therapro, Inc., Tumble N’ Dots, Inc., and Texthelp Ltd.

Recent News

A link between disrupted enzymes and intellectual disability has been discovered.

A study reveals how intellectual disability is caused by a rare genetic mutation in the enzyme called CaMKIIalpha. The P212L mutation leads to dramatically more activation and less inhibition of CaMKIIalpha, potentially leading to a potential treatment for intellectual disability. ScienceDaily

Estimating individual treatment effects on disability progression in multiple sclerosis using deep learning

In this study, predictive enrichment using a predictive deep-learning model increased the number of patients responding to medications in clinical trials by preferentially enrolling those predicted to have the best response. The model is validated by testing responses to anti-CD20 antibodies and laquinimod, which combined have an increased response rate of 37% over placebo based on biomarkers. Source: Nature

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global LDT Market Portraiture
2.2. Global LDT Market, by Therapy, 2018 (US$ Mn)
2.3. Global LDT Market, by Indication, 2018 (US$ Mn)
2.4. Global LDT Market, by Geography, 2018 (US$ Mn)

Chapter 3. Learning Disability Treatment (LDT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global LDT Market, by Key Players, 2018

Chapter 4. Global Learning Disability Treatment (LDT) Market, by Therapy
4.1. Overview
4.2. Stimulant Medication
4.3. Non Stimulant Medication
4.4. Orton-Gillingham Interventional Therapy
4.5. Occupational Therapy
4.6. Assistive Technology

Chapter 5. Global Learning Disability Treatment (LDT) Market, by Indication
5.1. Overview
5.2. Attention Deficit Hyperactivity Disorder (ADHD)
5.3. Dyslexia
5.4. Dyspraxia
5.5. Others

Chapter 6. Global Learning Disability Treatment (LDT) Market, by Geography
6.1. Overview
6.2. North America LDT Market Analysis, 2017 – 2027
6.2.1. North America LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.2.2. North America LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.2.3. North America LDT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe LDT Market Analysis, 2017 – 2027
6.3.1. Europe LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.3.2. Europe LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.3.3. Europe LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific LDT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.4.2. Asia Pacific LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.4.3. Asia Pacific LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America LDT Market Analysis, 2017– 2027
6.5.1. Latin America LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.5.2. Latin America LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.5.3. Latin America LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa LDT Market Analysis, 2017 – 2027
6.6.1. MEA LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.6.2. MEA LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.6.3. MEA LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Eli Lilly & Company
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. CogniFit
7.3. Forest Laboratories, Inc.
7.4. IMSE
7.5. Novartis AG
7.6. Pfizer, Inc.
7.7. Shire, Plc.
7.8. Therapro, Inc.
7.9. Tumble N’ Dots, Inc.
7.10. Texthelp Ltd.

List of Figures

FIG. 1 Learning Disability Treatment (LDT) Market: Research Methodology
FIG. 2 LDT: Market Segmentation
FIG. 3 Global LDT Market, by Therapy, 2018 (US$ Mn)
FIG. 4 Global LDT Market, by Indication, 2018 (US$ Mn)
FIG. 5 Global LDT Market, by Geography, 2018 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2018
FIG. 7 Competitive Analysis: Global LDT Market, by Key Players, 2018
FIG. 8 Global Stimulant Medication Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Non Stimulant Medication Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 10 Global Orton-Gillingham Interventional Therapy Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 11 Global Occupational Therapy Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 12 Global Assistive Technology Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 13 Global ADHD Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 14 Global Dyslexia Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 15 Global Dyspraxia Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 16 Global Other Indications Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 17 U.S. LDT Market, 2017 – 2027 (US$ Mn)
FIG. 18 Canada LDT Market, 2017 – 2027 (US$ Mn)
FIG. 19 U.K. LDT Market, 2017 – 2027 (US$ Mn)
FIG. 20 Germany LDT Market, 2017 – 2027 (US$ Mn)
FIG. 21 Rest of Europe LDT Market, 2017 – 2027 (US$ Mn)
FIG. 22 China LDT Market, 2017 – 2027 (US$ Mn)
FIG. 23 Japan LDT Market, 2017 – 2027 (US$ Mn)
FIG. 24 Rest of Asia Pacific LDT Market, 2017 – 2027 (US$ Mn)
FIG. 25 Brazil LDT Market, 2017 – 2027 (US$ Mn)
FIG. 26 Mexico LDT Market, 2017 – 2027 (US$ Mn)
FIG. 27 Rest of Latin America LDT Market, 2017 – 2027 (US$ Mn)
FIG. 28 GCC LDT Market, 2017 – 2027 (US$ Mn)
FIG. 29 Rest of MEA LDT Market, 2017 – 2027 (US$ Mn)

List of Tables

TABLE 1 Global Learning Disability Treatment (LDT) Market Portraiture
TABLE 2 Global LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 3 Global LDT Market , by Indication, 2017 – 2027 (US$ Mn)
TABLE 4 Global LDT Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 5 North America LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 6 North America LDT Market, by Indication, 2017 – 2027 (US$ Mn)
TABLE 7 North America LDT Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 8 Europe LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 9 Europe LDT Market, by Indication, 2017 – 2027 (US$ Mn)
TABLE 10 Europe LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 11 Asia Pacific LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 12 Asia Pacific LDT Market, by Indication, 2017 – 2027 US$ Mn)
TABLE 13 Asia Pacific LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 14 Latin America LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 15 Latin America LDT Market, by Indication, 2017 – 2027 (US$ Mn)
TABLE 16 Latin America LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 17 Middle East and Africa LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 18 Middle East and Africa LDT Market, by Indication, 2017 – 2027 (US$ Mn)
TABLE 19 Middle East and Africa LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 20 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 CogniFit: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Forest Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 IMSE: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Shire, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Therapro, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Tumble N’ Dots, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Texthelp Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)